CSF3 and myelodysplastic syndrome: While intermediate- and high-risk MDS patients often receive aggressive treatments such as hypomethylating agents or allogeneic stem cell transplantation, supportive therapies—including blood transfusions, iron chelation, erythropoiesis-stimulating agents (ESAs), granulocyte colony-stimulating factor (G-CSF), and thrombopoietin—may be sufficient for low-risk patients [5, 6].